Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 42.12 as of 2026-10-05T10:50:31.056Z.
Consensus retrieved: 2026-10-04T21:20:05.855Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-05T10:50:31.056Z.
Quote observation: 2026-10-02T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 49eba324224a3154c2946aeaa7b2ea8ca99dc2d017fdd5025060ec0ea8a52c68
Forward PE Ratio (42.12) = Dated Quote Price ($97.67) / Consensus Forward EPS ($2.32)
FORWARD PE RATIO
42.12
SECTOR MEDIAN · HEALTHCARE
19.60
median of 83 covered companies
CURRENT VS SECTOR MEDIAN
+114.90%
vs the sector median at left
Hinge Health, Inc.
Market Cap
$7.56B
Forward PE Ratio
42.12
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Hinge Health, Inc. (HNGE) | $7.56B | 42.12 |
| Oscar Health, Inc. (OSCR)vs › | $8.02B | 16.21 |
| Chemed Corporation (CHE)vs › | $6.63B | 19.91 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.47B | N/A |
| Insulet Corp. (PODD)vs › | $9.12B | 20.25 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.61B | N/A |
| Henry Schein, Inc. (HSIC)vs › | $9.67B | 15.76 |
| CRISPR Therapeutics AG (CRSP)vs › | $5.35B | N/A |
| Doximity, Inc. (DOCS)vs › | $5.22B | 20.73 |
| Molina Healthcare, Inc. (MOH)vs › | $9.89B | N/A |
Trailing P/E
75.9
reported TTM EPS
Forward P/E
42.1
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.32 implies +79.8% EPS growth vs the reported trailing $1.29.
At the dated quote price of $97.67, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.32 | $2.18 – $2.62 | 10 | 42.1x |
| 2027-12-31 | $2.93 | $2.62 – $3.32 | 9 | 33.4x |
| 2028-12-31 | $4.45 | $3.04 – $5.68 | 4 | 22.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
